An Open Label Randomised Phase II Trial of RNActive Cancer Vaccine (CV9104) in High Risk and Intermediate Risk Patients With Prostate Cancer

Trial Profile

An Open Label Randomised Phase II Trial of RNActive Cancer Vaccine (CV9104) in High Risk and Intermediate Risk Patients With Prostate Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs CV 9104 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors CureVac
  • Most Recent Events

    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
    • 10 Jun 2017 Biomarkers information updated
    • 29 Apr 2016 Status changed from active, no longer recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top